Bioperfectus deliver strong financial performance in the first half of 2022

Company news
2022-08-31

Bioperfectus deliver strong financial performance in the first half of 2022.

 

Download the 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐨𝐟 𝐉𝐢𝐚𝐧𝐠𝐬𝐮 𝐁𝐢𝐨𝐏𝐞𝐫𝐟𝐞𝐜𝐭𝐮𝐬 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐢𝐞𝐬 𝐂𝐨., 𝐋𝐭𝐝. (𝐒𝐒𝐄:𝟔𝟖𝟖𝟑𝟗𝟗) 𝐒𝐞𝐦𝐢-𝐀𝐧𝐧𝐮𝐚𝐥 𝐇𝟏 𝟐𝟎𝟐𝟐 𝐑𝐞𝐩𝐨𝐫𝐭 by clicking here.

MOST READ

Bioperfectus Extraction Solutions, One-Stop to Satisfy Your Requirements

Nucleic acid extraction provides a foundation for many extensive research and applications (for example cloning, PCR analysis, and next-generation sequencing technology in the field of whole genome and transcriptome), and the obtained nucleic acid can be used in a variety of ways. Nucleic acid purification and quality assessment are important steps in experimental workflows, and the quality of nucleic acids can affect the performance in downstream reactions.

2022-09-21

Client Story: G Company and Bioperfectus Success Story

Infectious diseases spread rapidly, and individuals with viruses can spread the infection to many other people in their community. Bioperfectus is still in a race against time and a guardian of humankind.

2022-09-20

SAW-96, More Than a Nucleic Acid Extraction Workstation

Nowadays, emerging infectious diseases significantly threaten global public health and socioeconomic security and will change how people live. COVID-19 is a notable example. There might also have an outbreak of Monkeypox based on the current situation. When a disease outbreak occurs, PCR would be a suitable way to accurately identify the pathogen and detect it in the early stage.

2022-09-20